Low testosterone and the association with type 2 diabetes

Diabetes Educator

Volumn 34, Issue 5, 2008, Pages 799-806

  Farrell, Joanne B ^a   Deshmukh, Anjali ^a   Baghaie, Ali A ^a  

^a Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

AFFECT; ARTICLE; BLOOD; HUMAN; HYPOGONADISM; LIBIDO; MALE; MASS SCREENING; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; UNITED STATES;

AFFECT; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGONADISM; LIBIDO; MALE; MASS SCREENING; PREVALENCE; QUESTIONNAIRES; TESTOSTERONE; UNITED STATES;

EID: 52349103202     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721708323100     Document Type: Article

References (46)

1. Winters SJ, Clark BJ Chapter 1. In: Bagatell C, Bremner W, eds. Androgens in Health and Disease. New York, NY: Humana Press; 2003: 3-22.
2. Mulligan T., Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006 ; 60 (7). 762-769.
3. Bhasin S., Cunningham GC, Hayes FJ, et al. Guidelines for testosterone therapy for androgen deficiency syndromes. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2006 ; 91: 1995-2010.
4. Anawalt BD Chapter 22. In: Bagatell C, Bremner W, eds. Androgens in Health and Disease. New York, NY: Humana Press; 2003: 419-438.
5. Braunstein GD Chapter 13. In: Greenspan F, ed. Basic & Clinical Endocrinology. 8 th ed. New York, NY: Lange / McGraw-Hill ; 2007: 470-501.
6. US Food and Drug Administration Updates. 1996. Skin patch replaces testosterone. http://www.fda.gov/fdac/departs/196_upd.html
7. American Diabetes Association. 2007. http://www.diabetes.org/about- diabetes.jsp
8. Narayan KM, Boyle JP, Geiss LS, et al. Impact of recent increase in incidence on future diabetes burden. Diabetes Care. 2006 ; 29 (9). 2114-2116.
9. Corona G., Mannucci E., Petrone L., et al. Association of hypogonadism and type 2 diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res. 2006 ; 18: 190-197.
10. Tomar R., Dhindsa S., Chaudhuri A., Mohanty P., Garg R., Dandona P. Contrasting testosterone concentrations in type 1 and type 2 diabetes. Diabetes Care. 2006 ; 29 (5). 1120-1122.
11. Kapoor D., Maklin CJ, Channer KS, et al. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol. 2005 ; 63: 29-250.
12. Kapoor D., Goodwin E., Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006 ; 154: 899-906.
13. Pitteloud N., Hardin M., Dwyer AA, et al. Insulin resistance is association with a decrease in leydig cell testosterone secretion in men. J Clin Endocrinol Metab. 2005 ; 90 (5). 2636-2641.
14. Stellato RK, Feldman HA, Hamdy O., et al. Testosterone, sex hormone-binding globulin and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care. 2000 ; 23 (4). 490-494.
15. Muller M., Grobbee DE, denTonkelaar I., et al. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005 ; 90 (5). 2618-2623.
16. Boyanov MA, Boneva Z., Christov VG Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003 ; 6: 1-7.
17. Corrales JJ, Burgo RM, Garca-Berrocal B., et al. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism. 2004 ; 53 (5). 666-672.
18. Abate N., Haffner SM, Garg A., et al. Sex steroid hormones, upper body obesity and insulin resistance. J Clin Endocrinol Metab. 2002 ; 87 (10). 4522-4527.
19. Betancourt-Albrecht M., Cunningham G. Hypogonadism and diabetes. Int J Impot Res. 2001 ; 15 (suppl 4). S14 - S20.
20. Gould DC, Kirby RS, Amoroso P. Hypoandrogen-metabolic syndrome: a potentially common and underdiagnosed condition in men. Int J Clin Pract. 2007 ; 61 (2). 341-344.
21. Petak SM, Nankin HR, Spark RF, et al. American association of clinical endocrinologists' medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocrine Pract. 2002 ; 8 (6). 439-456.
22. Hayes FJ Low testosterone tough on insulin sensitivity. Diabetes Forecast. 2007 ; 2: 63-67.
23. Dhindsa S., Prabhakar S., Sethi M., et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2004 ; 89 (11). 5462-5468.
24. Selvin E., Feinleib M., Zhang L., et al. Androgens and diabetes in men. Diabetes Care. 2007 ; 30 (2). 234-238.
25. Ding EL, Song Y., Malik VS, et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006 ; 295 (11). 1288-1299.
26. Kapoor D., Aldred H., Clark S., et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes. Diabetes Care. 2007 ; 30 (4). 911-917.
27. Morley JE, Charlton E., Patrick P., et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000 ; 49: 1239-1262.
28. Barrett-Connor E., Khaw KT, Yen SS Endogenous sex hormone levels in older adult men with diabetes mellitus. Am J Epidemiol. 1990 ; 132 (5). 895-901.
29. Ohl DA, Quallich SA Clinical hypogonadism and androgen replacement therapy: an overview. Urol Nurs. 2006 ; 26 (4). 243-260.
30. Leichtnam ML, Rolland H., Wuthrich P., et al. Testosterone hormone replacement therapy: state-of-the-art and emerging technologies. Pharmaceut Res. 2006 ; 23 (6). 1117-1132.
31. Margo K., Winn R. Testosterone treatments: why, when and how ? Am Fam Physician. 2006 ; 73 (9). 1591-1598.
32. Cunningham GR Testosterone replacement therapy for late-onset hypogonadism. Nat Clin Pract Urol. 2006 ; 3 (5). 260-267.
33. AndroGel® 1% CIII [package insert]. Marietta, GA: Solvay Pharmaceuticals ; 2007.
34. Testim® 1% [package insert]. Norristown, PA: Auxillium Pharmaceuticals ; 2003.
35. Striant™ [package insert]. Livingston, NJ: Columbia Laboratories ; 2003.
36. Androderm® [package insert]. Corona, CA: Watson Pharmaceuticals ; 2005.
37. Kaminetsky JC Benefits of a new testosterone gel formulation for hypogonadal men. Clin Cornerstone. 2005 ; 7 (suppl 4). S8 - S12.
38. Comparison of testosterone replacement products. The Pharmacist's Letter. 2003: 19.
39. Cunningham GR Male hypogonadism: management strategies. News & views on male testosterone deficiency. A Supplement to Renal &Urology News. 2006 ; 1 ( 3 ).
40. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004 ; 350 (5). 482-492.
41. Karpman E., Lipshultz LI, Williams DH The challenges of hypogonadism and its comorbidities. First Report. March 2006.
42. Kalyani RR, Gavini S., Dobs AS Male hypogonadism in systemic disease. Endocrinol Metab Clin North Am. 2007 ; 36 (6). 333-348.
43. Drugs Information On-line. 2007. http://www.drugs.com/alpha/t5.html? filter.
44. Take Charge. Talk T. 2007. Brochure available through American Association of Diabetes Educators.
45. Hormone Foundation's Patient Guide to Androgen Deficiency Syndromes in Adult Men. www.hormone.org.
46. Mayo Men's Health Center. www.mayoclinic.com.